A C Rawstron
Overview
Explore the profile of A C Rawstron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
873
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rawstron A, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder J, et al.
Leukemia
. 2007 Mar;
21(5):956-64.
PMID: 17361231
The eradication of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) predicts for improved outcome. However, the wide variety of MRD techniques makes it difficult to interpret and compare...
12.
Rawstron A, de Tute R, Jack A, Hillmen P
Leukemia
. 2006 Oct;
20(12):2102-10.
PMID: 17051247
Depletion of disease below the levels detected by sensitive minimal residual disease (MRD) assays is associated with prolonged survival in chronic lymphocytic leukaemia (CLL). Flow cytometric MRD assays are now...
13.
de Tute R, Yuille M, Catovsky D, Houlston R, Hillmen P, Rawstron A
Leukemia
. 2006 Jan;
20(4):728-9.
PMID: 16437141
No abstract available.
14.
Rawstron A
J Biol Regul Homeost Agents
. 2004 Oct;
18(2):155-60.
PMID: 15471220
Identifying and characterizing the earliest stages of disease is particularly important in disorders such as Chronic Lymphocytic Leukemia (CLL), where the initiating oncogenic events are unknown. Improvements in diagnostic technology...
15.
Fenton J, Pratt G, Rawstron A, Morgan G
Hematol Oncol
. 2002 Jul;
20(2):75-85.
PMID: 12111870
Translocations at the immunoglobulin heavy chain locus (14q32) are now considered the commonest karyotypic change in multiple myeloma. These translocations are thought to be intimately involved in the pathogenesis of...
16.
Pratt G, Rawstron A, English A, Johnson R, Jack A, Morgan G, et al.
Br J Haematol
. 2001 Sep;
114(4):937-43.
PMID: 11564089
In peripheral blood stem cell transplantation (PBSCT), the number of CD34+ cells transplanted has been shown to correlate well with both rapidity and durability of engraftment. However, it is clear...
17.
Rawstron A, Kennedy B, Evans P, Davies F, Richards S, Haynes A, et al.
Blood
. 2001 Jun;
98(1):29-35.
PMID: 11418459
Previous studies have suggested that the level of residual disease at the end of therapy predicts outcome in chronic lymphocytic leukemia (CLL). However, available methods for detecting CLL cells are...
18.
Rawstron A, Barrans S, Blythe D, English A, Richards S, Fenton J, et al.
Br J Haematol
. 2001 May;
113(3):794-802.
PMID: 11380472
The nature of the proliferating fraction in myeloma is still not known and understanding the characteristics of this fraction is central to the development of effective novel therapies. However, myeloma...
19.
Davies F, Forsyth P, Rawstron A, Owen R, Pratt G, Evans P, et al.
Br J Haematol
. 2001 Mar;
112(3):814-9.
PMID: 11260088
Initial studies with high-dose therapy (HDT) in myeloma suggest some beneficial effects of attaining a complete response (CR); however, the effect on survival is difficult to assess owing to inconsistencies...
20.
Pratt G, Fenton J, Davies F, Rawstron A, Richards S, Collins J, et al.
Br J Haematol
. 2001 Feb;
112(2):388-91.
PMID: 11167836
The majority of patients with multiple myeloma have translocations involving the immunoglobulin heavy chain switch regions on chromosome 14q32 and a promiscuous range of partner chromosomes. We describe a patient...